Bayesian Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bayesian Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$686K	–	845
2024 Q2	$686K	Buy	+5,000	New	+$667K	0.08%	299
2024 Q1	–	Sell	-2,122	Closed	-$288K	–	929
2023 Q4	$288K	Buy	+2,122	New	+$259K	0.03%	526
2022 Q4	–	Sell	-3,510	Closed	-$411K	–	884
2022 Q3	$411K	Sell	3,510 -2,779	-44%	-$345K	0.08%	333
2022 Q2	$740K	Buy	+6,289	New	+$747K	0.14%	229
2021 Q3	–	Sell	-3,400	Closed	-$556K	–	455
2021 Q2	$556K	Buy	+3,400	New	+$524K	0.15%	176
2020 Q4	–	Sell	-5,894	Closed	-$798K	–	555
2020 Q3	$798K	Buy	+5,894	New	+$800K	0.2%	141
2020 Q1	–	Sell	-3,572	Closed	-$430K	–	859
2019 Q4	$430K	Buy	+3,572	New	+$399K	0.07%	338

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Bayesian Capital Management's IBB Position: Q3 2024 in Review

Bayesian Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2024, closing a stake of 5,000 shares — an estimated $686K sold.

Bayesian Capital Management first reported a position in IBB in Q4 2019 and held it in 7 quarters. The position peaked at $798K in Q3 2020. 893 funds tracked by Wall St. Rank hold IBB as of Q3 2024.

Bayesian Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2024 after selling out during the quarter.
Bayesian Capital Management sold 5,000 iShares Biotechnology ETF shares in Q3 2024, an estimated $686K.
Bayesian Capital Management first reported a position in iShares Biotechnology ETF in Q4 2019 and held it in 7 quarters.
Bayesian Capital Management's iShares Biotechnology ETF position peaked at $798K in Q3 2020.
893 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.